De Corso Eugenio, Pipolo Carlotta, Cantone Elena, Ottaviano Giancarlo, Gallo Stefania, Canevari Frank Rikki Mauritz, Macchi Alberto, Monti Giulia, Cavaliere Carlo, La Mantia Ignazio, Torretta Sara, Bussu Francesco, Scarano Emanuele, Petrone Paolo, Ghidini Angelo, Lucidi Daniela, Garzaro Massimiliano, Trimarchi Matteo, Seccia Veronica, Passali Giulio Cesare, Salsi Daria, Cuda Domenico, Pasquini Ernesto, Malvezzi Luca, Settimi Stefano, Paludetti Gaetano, Galli Jacopo
Otorhinolaryngology Unit, Head and Neck Department, Fondazione Policlinico Universitario A. Gemelli Hospital IRCCS, 00168 Rome, Italy.
Otorhinolaryngology Unit, Head and Neck Department, ASST Santi Paolo e Carlo Hospital, 20142 Milan, Italy.
J Pers Med. 2022 May 29;12(6):897. doi: 10.3390/jpm12060897.
: Local and systemic corticosteroids have long been the workhorse in management of chronic rhinosinusitis with nasal polyps (CRSwNP), although there is no universally accepted modality of prescription. We carried out a survey in Italy to capture current trends in the use of topical and systemic corticosteroids in patients with CRSwNP. : A survey was set up on Survey Monkey. Each author distributed the link to the survey in an ad hoc manner and a total of 437 participants filled out the survey. : Mometasone furoate (79.3%) was the most frequently prescribed, administered daily by 61.9% of participants; the remaining preferred to discontinue treatment for brief periods to reduce side effects or to modulate the therapy in mild cases. The majority believe that a short cycle of systemic steroids should be prescribed for re-exacerbation of symptoms and that the number of cycles in the previous year should be evaluated to define control of the disease even if international guidelines do not provide clear indications on this topic. A certain degree of divergence emerged from responses regarding how long and the maximal dose of systemic steroids which place patients at high risk for adverse events. Finally, systemic corticosteroids seem to offer only temporary benefit on recovery of smell without guaranteeing long-term control even if the patient is adherent to topical corticosteroids. : Our results highlight the need for clear guidelines on oral steroids, which could help supporting the use of a precision medicine approach, including indications for new biological agents.
局部和全身用糖皮质激素长期以来一直是治疗伴有鼻息肉的慢性鼻-鼻窦炎(CRSwNP)的主要药物,尽管目前尚无普遍接受的处方方式。我们在意大利开展了一项调查,以了解CRSwNP患者局部和全身用糖皮质激素的当前使用趋势。
在Survey Monkey上设置了一项调查。每位作者以特定方式分发了调查链接,共有437名参与者填写了调查问卷。
糠酸莫米松(79.3%)是最常被处方的药物,61.9%的参与者每天使用;其余参与者倾向于在短时间内停药以减少副作用或在轻症病例中调整治疗方案。大多数人认为,对于症状再次加重的情况,应开具短期全身用糖皮质激素疗程,并且即使国际指南未就此主题提供明确指示,也应评估上一年的疗程数来确定疾病的控制情况。在全身用糖皮质激素的使用时长和最大剂量方面,这些因素会使患者出现不良事件的风险增加,对此问题的回答存在一定程度的分歧。最后,全身用糖皮质激素似乎仅能在嗅觉恢复方面提供暂时的益处,即使患者坚持使用局部用糖皮质激素,也无法保证长期控制。
我们的研究结果凸显了制定关于口服糖皮质激素的明确指南的必要性,这有助于支持精准医学方法的应用,包括新型生物制剂的适应证。